News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2021

April

Media Release / Apr 29, 2021

Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still’s disease

Read More
Media Release / Apr 28, 2021

Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah® (tisagenlecleucel)i

Read More
Media Release / Apr 13, 2021

Novartis in Canada named a Top 50 Best Workplace™ in the country

Read More

March

Media Release / Mar 23, 2021

Health Canada approves Kesimpta®, the first and only self-administered targeted B-cell therapy for relapsing remitting multiple sclerosis (RRMS)

Read More
Media Release / Mar 18, 2021

Novartis’ KISQALI® (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer

Read More
2020

December

Media Release / Dec 16, 2020

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Read More

November

Media Release / Nov 02, 2020

Novartis’ MONALEESA-7 KISQALI® (ribociclib) study demonstrated statistically significant improvement in overall survival in pre- and perimenopausal women with HR+/HER2- advanced breast cancer

Read More

October

Media Release / Oct 21, 2020

Novartis in Canada driving digital healthcare solutions with the inauguration of a Biome innovation hub

Read More
Media Release / Oct 16, 2020

Health Canada approves first-ever gene replacement therapy, Luxturna®

Read More
Media Release / Oct 02, 2020

Next-generation wet AMD therapy PrBeovu® now available in Canada receives positive recommendation from CADTH Drug Expert Committee1

Read More